EUS-guided intraportal infusion of autologous bone marrow in patients with decompensated liver cirrhosis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035269

Enrollment

Unknown

Registered

2020-08-06

Start date

2018-12-27

Completion date

Unknown

Last updated

2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decompensated Liver Cirrhosis

Interventions

Case series:EUS-guided intraportal infusion of autologous bone marrow

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >18 years; 2. DLC marked by the development of overt clinical signs such as ascites, gastrointestinal bleeding, and jaundice; 3. Etiology: alcoholic or posthepatitic cirrhosis; 4. Endoscopy was tolerable after anesthesia evaluation.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with severe anemia and coagulation dysfunction that could not be improved after treatment; 3. Failure of hemostasis treatment for gastrointestinal bleeding in the past month; 4. Presence of spontaneous peritonitis, hepatic encephalopathy, hepatorenal syndrome and acute infection; 5. Presence of coexisting severe heart, lung, kidney, blood system or other diseases, history of mental illness; 6. Malignant tumor of the liver or other organs.

Design outcomes

Primary

Measure	Time frame
survival time;	—

Secondary

Measure	Time frame
liver function;coagulation profile;routine blood test;liver fibrotest;ascites;portal vein diameter;neoplastic lesions;portal vein thrombosis;liver stiffness;fat attenuation parameters;	—

Countries

China

Contacts

Public ContactFen Wang

Department of gastroenteropathy, The Third Xiangya Hospital of Central South University

wfen-judy@csu.edu.cn+86 18229975500

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026